期刊文献+

宫颈癌新辅助化疗疗效分析 被引量:35

Analysis of effect of neoadjuvant chemotherapy in the treatment of cervical cancer
暂未订购
导出
摘要 目的探讨ⅠB2~ⅡB期宫颈癌术前化疗联合手术治疗疗效。方法回顾性分析2005年6月至2009年4月在北京大学人民医院手术治疗的66例ⅠB2~ⅡB期宫颈癌患者的病例资料,根据术前是否行化疗,分为术前化疗组(研究组)和直接手术组(对照组),评价新辅助化疗组的近期疗效,比较两组的手术时间、术中出血量、盆腔淋巴结转移率、脉管癌栓阳性率、宫旁及阴道断端有无癌转移等。结果 41例宫颈癌患者术前行新辅助化疗的总临床有效率为58.54%(24/41),完全缓解率为4.87%(2/41),部分缓解率为53.65%(22/41),病情稳定36.58%(15/41),疾病进展4.87%(2/41)。研究组淋巴、脉管癌栓转移率36.58%(15/41),对照组72.00%(18/25),研究组低于对照组,差异有统计学意义(P<0.05),手术时间、出血量差异无统计学意义(P>0.05)。结论宫颈癌患者术前行新辅助化疗可有效缩小病灶,降低淋巴、脉管内癌栓转移率。 Objective To assess the effect of neoadjuvant chemotherapy (NACT) in the treatment of stage Ⅰ B2-Ⅱ B cervical cancer. Methods 66 patients diagnosed with stage Ⅰ B2~Ⅱ B cervical cancer and treated at Peking University People's Hospital from June, 2005 to April, 2009 were reviewed. The patients were divided into study group who received NACT prior to surgery (NACT group) and control group who received primary surgery treatment (PST group). The recent effect of NACT was estimated by analyzing the operation time, the amount of bleeding, the metastasis rate of pelvic lymph nodes, the rate of lymph-vascular space involvement (LVSI), the metastasis of parametrium and vaginal cuff.Results Of the 66 patients,41 patients received NACT,among them the clinical total effective rate was 58.54%(24/41),the complete remission rates was 4.87%(2/41),the partial remission rate was 53.65%(22/41),15 of which were in stable condition(36.58%) and 2 were in progression(4.87%). Compared with patients treated by PST, the estimated blood loss, operation time, number of lymph nodes removed and the complication rates during and after surgery in NACT patients had no significant difference. The LVSI rate was 36.58% (15/41) in NACT group, which was significant lower than that in the PST group (72.00%,18/25,P0.05).Conclusions NACT in the treatment of cervical cancer can effectively reduce tumor volume and reduce the rate of LVSI.
出处 《中国妇产科临床杂志》 2013年第1期20-22,共3页 Chinese Journal of Clinical Obstetrics and Gynecology
基金 北京市科委2009年科技重大项目(D090507043409007)
关键词 宫颈癌 新辅助化疗 手术治疗 cervical cancer neoadjuvant chemotherapy surgical treatment
  • 相关文献

参考文献9

  • 1Parkin DM,Bray F,Ferlay J. Global cancer statistics,2002[J].CA:A Cancer Journal for Clinicians,2005.74-108.
  • 2Benedetti-Panici P,Scambia G,Greggi S. Neoadjuvant chemotherapy and radical surgery in locally advanced cervical carcinoma:a pilot study[J].Obstetrics and Gynecology,1988.344-348.
  • 3郄明蓉.宫颈癌新辅助化疗及其对手术的影响[J].中国妇产科临床杂志,2009,10(5):397-399. 被引量:6
  • 4Huang HJ,Chang TC,Hong JH. Prognostic value of ageand histologic type in neoadjuvant chemotherapy plus radical surgery for bulk (≥4 cm) stage ⅠB and ⅡA cervicalcancer[J].International Journal of Gynecological Cancer,2003.204.
  • 5Sasoka M,Fuwa N,Asuno A. Patterns of failure in carcinoma of the uterine cervix treated with definitive radiotherapy alone[J].American Journal of Clinical Oncology,2001.586.
  • 6Lehman M,Thomas G. Is concurrent chemotherapy and radiotherapy the new standard of cwere for locally advanced cervical cancer [J].International Journal of Gynecological Cancer,2001.87.
  • 7程晓东,吕卫国,叶枫,陈怀增,谢幸.局部晚期子宫颈癌新辅助化疗价值的评估[J].中华妇产科杂志,2006,41(2):95-98. 被引量:66
  • 8林仲秋,吴珠娜.FIGO 2009外阴癌、宫颈癌和子宫内膜癌新分期解读[J].国际妇产科学杂志,2009,36(5):411-412. 被引量:81
  • 9Chen H,Liang C,Zhang L. Clinical efficacy of modified preoperative neoadjuvant chemotherapy in t he t reatment of locally advanced (stage ⅠB2 to ⅡB) cervical cancer:randomized study[J].Gynecologic Oncology,2008.308-315.

二级参考文献29

  • 1王平,彭芝兰,张家文,刘辉,张崇淑,曹泽毅.子宫颈癌新辅助化疗中不同化疗途径的疗效比较[J].中华妇产科杂志,2005,40(4):227-230. 被引量:109
  • 2Frei E 3rd. Clinical cancer research: an embattled species. Cancer, 1982, 50: 1979-1992.
  • 3Palaia I, PerniceM, GrazianoM, et al. Neoadjuvant chemotherapy plus radical surgery in locally advanced cervical cancer during pregnancy: a case report. Am J Obstet Gynecol, 2007, 197: e5-6.
  • 4Plante M, Lau S, Brydon L, et al. Neoadjuvant chemotherapy followed by vaginal radical trachelectomy in bulky stage IB1 cervical cancer: case report. Gynecol Oncol, 2006, 101: 367 - 370.
  • 5Benedetti Panici P, Bellati F, Pastore M, et al. An update in neoadjuvant chemotherapy in cervical cancer. Gynecol Oncot, 2007, 107 (Suppl 1): S20-22.
  • 6Long HJ, Bundy BN, Grendys EC, et al. Randomized phase Ⅲ trial of cisplatin with or without topotecan in carcinoma of the uterine cervix:a Gynecologic Oncology Group Study. J Clin Oncol, 2005, 23: 4626-4633.
  • 7Monk B, Huang HQ, Cella D, et al. Quality of life outcomes from a randomized phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: a Gynecologic Oncology Group Study. J Clin Oncol, 2005, 23: 4617 - 4625.
  • 8Buda A, Fossati R, Colombo N, et al. Randomized trial of neoadjuvant chemotherapy comparing paclitaxel, ifosfamide, and cisplatin with ifosfamide and cisplatin followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the SNAP01 (Studio Neo- Adiuvante Portio) Italian Collaborative Study. J Clin Oncol, 2005, 23:4137 - 4145.
  • 9Malzoni M, Spina V, Perniola G, et al. Laparoscopic surgery in treatment of stage II b cervical cancer after neoadjuvant chemotherapy. A case report and review of the literature. EurJGynecolOncol, 2003, 24: 393-397.
  • 10Slama J, Cibula D, Freitag P, et al. Contribution of neoadjuvant chemotherapy for operability of cancers of the uterine cervix. Ceska Gynekol, 2007, 72:116- 119.

共引文献147

同被引文献364

引证文献35

二级引证文献254

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部